JP2022509065A5 - - Google Patents

Info

Publication number
JP2022509065A5
JP2022509065A5 JP2021526658A JP2021526658A JP2022509065A5 JP 2022509065 A5 JP2022509065 A5 JP 2022509065A5 JP 2021526658 A JP2021526658 A JP 2021526658A JP 2021526658 A JP2021526658 A JP 2021526658A JP 2022509065 A5 JP2022509065 A5 JP 2022509065A5
Authority
JP
Japan
Application number
JP2021526658A
Other languages
Japanese (ja)
Other versions
JP7451520B2 (ja
JPWO2020099653A5 (https=
JP2022509065A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/081523 external-priority patent/WO2020099653A1/en
Publication of JP2022509065A publication Critical patent/JP2022509065A/ja
Publication of JP2022509065A5 publication Critical patent/JP2022509065A5/ja
Publication of JPWO2020099653A5 publication Critical patent/JPWO2020099653A5/ja
Application granted granted Critical
Publication of JP7451520B2 publication Critical patent/JP7451520B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021526658A 2018-11-15 2019-11-15 ヒト化抗SIRPα抗体 Active JP7451520B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18206594 2018-11-15
EP18206594.6 2018-11-15
PCT/EP2019/081523 WO2020099653A1 (en) 2018-11-15 2019-11-15 HUMANIZED ANTI-SIRPα ANTIBODIES

Publications (4)

Publication Number Publication Date
JP2022509065A JP2022509065A (ja) 2022-01-20
JP2022509065A5 true JP2022509065A5 (https=) 2022-11-02
JPWO2020099653A5 JPWO2020099653A5 (https=) 2022-11-02
JP7451520B2 JP7451520B2 (ja) 2024-03-18

Family

ID=64331834

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021526658A Active JP7451520B2 (ja) 2018-11-15 2019-11-15 ヒト化抗SIRPα抗体

Country Status (13)

Country Link
US (1) US12180295B2 (https=)
EP (1) EP3880707A1 (https=)
JP (1) JP7451520B2 (https=)
CN (1) CN113412279B (https=)
AU (1) AU2019378101B2 (https=)
BR (1) BR112021009275A2 (https=)
CA (1) CA3118966A1 (https=)
CL (1) CL2021001260A1 (https=)
IL (1) IL282756A (https=)
MX (1) MX2021005761A (https=)
MY (1) MY204673A (https=)
SG (1) SG11202104431PA (https=)
WO (1) WO2020099653A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66062B1 (sr) 2016-04-14 2024-11-29 Ose Immunotherapeutics Nova anti-sirpa antitela i njihove terapijske primene
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CN118027200A (zh) 2016-12-09 2024-05-14 艾利妥 抗SIRPα抗体及其使用方法
CN118267470A (zh) * 2017-04-13 2024-07-02 赛罗帕私人有限公司 抗SIRPα抗体
MX2020009774A (es) 2018-03-21 2020-10-08 Alx Oncology Inc Anticuerpos contra proteína alfa reguladora de señal y métodos de uso.
EP3802602A1 (en) 2018-05-25 2021-04-14 Alector LLC Anti-sirpa antibodies and methods of use thereof
AU2021378152A1 (en) * 2020-11-11 2023-06-22 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY
CN112574310B (zh) * 2020-12-11 2023-05-05 浙江博锐生物制药有限公司 抗SIRPα抗体及其用途
CN114790241B (zh) * 2021-01-26 2024-12-13 北京免疫方舟医药科技有限公司 抗tigit抗体及其应用
BR112023025194A2 (pt) * 2021-06-04 2024-02-27 Boehringer Ingelheim Int Anticorpos anti-sirp-alfa
EP4619435A1 (en) 2022-11-16 2025-09-24 Boehringer Ingelheim International GmbH Predictive efficacy biomarkers for anti-sirpa antibodies

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU1701001A (en) 1999-11-30 2001-06-12 Eberhard-Karls-Universitat Tubingen Universitatsklinikum Antibodies against signal regulator proteins
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
DK2474557T3 (da) 2007-07-16 2014-11-10 Genentech Inc Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
CA2752373C (en) 2009-02-20 2017-10-10 To-Bbb Holding B.V. Glutathione-based drug delivery system
CN101880324B (zh) * 2010-05-25 2012-10-17 中国人民解放军第二军医大学 一种抗人SIRPα的单克隆抗体及其细胞株、制备方法和应用
RU2597831C2 (ru) 2011-01-19 2016-09-20 Кантаргия Аб Анти-il1rap антитела и их применение при лечении людей
MX2013014789A (es) * 2011-06-16 2014-01-20 Novartis Ag Proteinas solubles para utilizarse como productos terapeuticos.
WO2013056352A1 (en) 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
WO2013150043A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
EP3795215A1 (en) 2012-05-30 2021-03-24 Chugai Seiyaku Kabushiki Kaisha Target tissue-specific antigen-binding molecule
MX2015008534A (es) 2012-12-26 2017-07-04 Oncosynergy Inc COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS.
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN103665165B (zh) * 2013-08-28 2016-02-24 江苏匡亚生物医药科技有限公司 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途
AU2015229448B2 (en) * 2014-03-11 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies
HUE046661T2 (hu) * 2014-08-15 2020-03-30 Merck Patent Gmbh SIRP-alfa immunglobulin fúziós proteinek
CA2994935A1 (en) 2015-05-18 2016-11-24 Ab Initio Biotherapeutics, Inc. Sirp polypeptide compositions and methods of use
JP7078533B2 (ja) 2015-10-21 2022-05-31 オーエスイー イムノセラピューティクス 炎症促進性細胞へのマクロファージ分極を改変して癌を治療するための抗SIRPa化合物
SG11201808465UA (en) * 2016-04-14 2018-10-30 Ose Immunotherapeutics NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
KR102878970B1 (ko) 2016-08-03 2025-10-30 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항-SIRPalpha 항체 요법의 대식세포 증진 효능에서 Fc 수용체 참여의 붕괴
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CN118027200A (zh) * 2016-12-09 2024-05-14 艾利妥 抗SIRPα抗体及其使用方法
CN118267470A (zh) * 2017-04-13 2024-07-02 赛罗帕私人有限公司 抗SIRPα抗体
CN118271443A (zh) 2017-05-16 2024-07-02 拜奥迪斯私人有限公司 抗SIRPα抗体
WO2019023347A1 (en) 2017-07-26 2019-01-31 Forty Seven, Inc. ANTI-SIRP-ALPHA ANTIBODIES AND ASSOCIATED METHODS

Similar Documents

Publication Publication Date Title
BR112021017339A2 (https=)
BR112021017637A2 (https=)
JP2022509065A5 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)
BR112021017173A2 (https=)
BR112021017083A2 (https=)
BR112021015080A2 (https=)
BR112021018584A2 (https=)
BR112021017310A2 (https=)
BR112021018484A2 (https=)
AT524962A5 (https=)